Table 2.
Risk factors of renal complications and glucose-lowering treatments in the Austria/Germany, Swedish and US registries
| Austria/Germany (DPV), N = 24,566 | Sweden (NDR), N = 45,105 | US (T1DX), N = 9255 | |
|---|---|---|---|
| Age, years | 42.0 ± 20.1 | 47.0 ± 17.3 | 38.6 ± 17.9 |
| Sex % male | 53.0 | 55.6 | 47.2 |
| Diabetes duration, years | 16.4 ± 14.0 | 24.3 ± 15.6 | 22.1 ± 13.7 |
| HbA1c (% and mmol/mol) |
8.2 ± 2.0 66 ± 10.1 |
7.108 ± 1.2 62 ± 7.25 |
8.1 ± 1.6 65 ± 9.6 |
| On insulin pump, % | 20.1 | 22.8 | 63.4 |
| On CGM/isCGM, % | 8.4 | 57.3 | 30.7 |
|
Systolic blood pressure, mmHg ACEi/ARB use (mean) |
129.6 ± 16.9 38.12 |
127.0 ± 14.5 29.78 |
123.1 ± 14.3 16.09 |
| Previous CVD, % | 16.0 | 5.5 | 7.5 |
|
Microalbuminuria, % (95% CI) |
19.1 17.9–19.5% |
12.6 12.3–12.9% |
7.1 6.5–7.7% |
|
Macroalbuminuria, % (95% CI) |
5.4 4.9–5.7% |
4.1 3.9–4.3% |
1.2 0.9–1.4% |
| Renal function | |||
| eGFR (CKD-EPI), ml/min | 90.5 ± 31.2 | 95.1 ± 23.3 | 94.2 ± 26.0 |
| eGFR 60 to < 90 ml/min, % | 25.9 | 28.1 | 30.4 |
| eGFR 45 to < 60 ml/min, % | 7.3 | 4.2 | 5.1 |
| eGFR 30 to < 45 ml/min, % | 4.9 | 2.1 | 2.6 |
| eGFR < 30 ml/min, % | 5.1 | 1.5 | 2.1 |